AMPH Q3 2017 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q3 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$58M-9.8% YoY

Gross Profit

$21M35.6% margin

Operating Income

-$3M-4.9% margin

Net Income

$175,0000.3% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

-11.2%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

-$9M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$438M

Total Liabilities

$107M

Stockholders' Equity

$331M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$58M	$64M	-9.8%
Gross Profit	$21M	$28M	-25.2%
Operating Income	-$3M	$6M	-148.6%
Net Income	$175,000	$4M	-95.5%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$3M100%

Geographic Segments

U

$55M100%